Showing results (121-130 of 168) with videos related to

Sort By:
Pageof 17
Oral Oncology|July 18, 2016
A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancerSjoukje F Oosting, Tom W W Chen, Shao H Huang, et al.
Nature Communications|May 13, 2026
Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trialAna C Veneziani, Stephanie Lheureux, Douglas G Millar, et al.
Molecular Cancer Therapeutics|March 4, 2010
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohortMiguel Quintela-Fandino, Christophe Le Tourneau, Ignacio Duran, et al.
Investigational New Drugs|June 13, 2016
Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)Amy Prawira, Irene Brana-Garcia, Anna Spreafico, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2019
<i>TP53</i> mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analysesVictoria Mandilaras, Swati Garg, Michael Cabanero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2011
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomasAnastasios Stathis, Sebastien J Hotte, Eric X Chen, et al.
Gynecologic Oncology|March 15, 2015
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortiaIvan Diaz-Padilla, Michelle K Wilson, Blaise A Clarke, et al.
JNCI Cancer Spectrum|May 31, 2021
Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With ImmunotherapyDaniel V Araujo, Ao Wang, Dax Torti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomasAnastasios Stathis, Sebastien J Hotte, Eric X Chen, et al.
Investigational New Drugs|May 3, 2014
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patientsAnna Spreafico, Kim N Chi, Srikala S Sridhar, et al.
Pageof 17